Hikma Pharmaceuticals Plc’s U.S. subsidiary raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines.
Thomas Wynn, after serving 26 years as a senior investigator at the National Institutes of Health (NIH), left to lead Pfizer’s inflammation and immunology unit.
A federal jury cleared Bayer and J&J of liability in the third case to go to trial out of thousands of lawsuits claiming their blood thinner Xarelto led to severe internal bleeding.
The Greater Than One Group (GTO) announced that James P. Plattner joined the firm as Global Chief Financial Officer.
Insys Therapeutics Inc. agreed to pay $4.45 million to resolve a lawsuit by Illinois’ attorney general claiming it deceptively marketed an addictive fentanyl-based cancer pain drug for off-label uses.
The Philippines found a second outbreak of bird flu in another province in the main Luzon island, Agriculture Secretary Emmanuel Pinol said, a week after reporting the country’s first case of the poultry disease.
The FDA expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co. Inc., and approved a new two-tablet regimen for the drug.
FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection
As an additional measure in the fight against Zika virus, the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
The U.S. Food and Drug Administration approved Pfizer Inc.’s rare blood cancer drug Besponsa with a boxed warning.
Lower levels of brain activity during childhood may lead to decreased self-control and, eventually, delinquent behavior in adolescence, according to a new study published by a team of researchers from FIU and the University of Michigan.